Skip to content

Clinical Application of Nicotinamide Adenine Dinucleotide(NAD+) in Ovarian Function Decline in Advanced Maternal Age: A Multicenter Randomized Controlled Study

Clinical Application of NAD+ in Ovarian Function Decline in Advanced Maternal Age: A Multicenter Randomized Controlled Study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500110036
Enrollment
Unknown
Registered
2025-09-29
Start date
2025-10-01
Completion date
Unknown
Last updated
2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Age-Related Diminished Ovarian Reserve

Interventions

Control Group:Conventional treatment protocols for assisted reproductive technology.
Observation Group 1:On the basis of the conventional treatment regimen, starting from the first day of entering the assisted reproductive technology (ART) cycle and continuing until the trigger day, t
Observation Group 2:On the basis of the conventional treatment regimen, injectable Coenzyme I was administered 60 days in advance. The administration was via intramuscular injection, with a dosage of

Sponsors

Qinzhou Maternity and Child Healthcare Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
35 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age>35 years; 2. Comply with IVF/ICSI indications; 3. Body mass index (BMI)>=18 kg/m^2 and <=38 kg/m^2; 4.AMH < 1.2 ng/ml; 5. Sinus follicle count (AFC) < 7; 6. 10 mIU/ml < FSH < 25 mIU/ml; 7. Agree to participate in this study and be willing to complete follow-up visits.

Exclusion criteria

Exclusion criteria: 1. Pregnancy; 2. Premature ovarian failure due to genetic causes: such as Turner syndrome or chromosomal abnormalities;Underlying diseases: blood diseases, significant thrombocytopenia, diabetes, hypertension, thyroid diseases, thrombotic diseases, tumor diseases, autoimmune diseases; 3. Uterine malformations or lesions (such as submucosal fibroids, endometrial hyperplasia, endometrial effusion or endometrial adhesions, thin endometrium); 4. Male oligoasthenospermia or azoospermia; 5. Those who are allergic to Coenzyme I and its derivatives; 6. Those who have other contraindications to assisted reproductive technology.

Design outcomes

Primary

MeasureTime frame
Clinical pregnancy rate;

Secondary

MeasureTime frame
Number of oocytes retrieved;Number of MII oocytes;Number of GV oocytes;Number of other abnormal oocytes;Number of viable embryos;Number of transferable embryos;Number of embryos cultured to blastoc;Number of high-quality blastocysts;Number of blastocysts formed;Number of cryopreserved blastocysts;Biochemical pregnancy rate;Ectopic pregnancy rate;Combined intrauterine and extrauterine pregnancy rate;Early miscarriage rate;

Countries

China

Contacts

Public ContactHongbo Wu

Qinzhou Maternity and Child Healthcare Hospital

wuhongbo20212021@163.com+86 777 239 1223

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026